These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 37656319)
1. Update of Gepants in the Treatment of Chronic Migraine. Cho S; Kim BK Curr Pain Headache Rep; 2023 Oct; 27(10):561-569. PubMed ID: 37656319 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Porreca F; Navratilova E; Hirman J; van den Brink AM; Lipton RB; Dodick DW Cephalalgia; 2024 Mar; 44(3):3331024241238153. PubMed ID: 38477313 [TBL] [Abstract][Full Text] [Related]
3. Gepants - a long way to cure: a narrative review. Altamura C; Brunelli N; Marcosano M; Fofi L; Vernieri F Neurol Sci; 2022 Sep; 43(9):5697-5708. PubMed ID: 35650458 [TBL] [Abstract][Full Text] [Related]
4. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? Moreno-Ajona D; Pérez-Rodríguez A; Goadsby PJ Curr Opin Neurol; 2020 Jun; 33(3):309-315. PubMed ID: 32251023 [TBL] [Abstract][Full Text] [Related]
9. Atogepant: Mechanism of action, clinical and translational science. Boinpally R; Shebley M; Trugman JM Clin Transl Sci; 2024 Jan; 17(1):e13707. PubMed ID: 38266063 [TBL] [Abstract][Full Text] [Related]
10. Update on gepants for the treatment of chronic migraine. Aoh Y; Hou TW; Yang CC; Chang CM; Chen SP; Tsai IJ; Cheng CW; Yang CP J Chin Med Assoc; 2024 Apr; 87(4):350-356. PubMed ID: 38349136 [TBL] [Abstract][Full Text] [Related]
11. The pharmacotherapeutic management of episodic and chronic migraine with gepants. Tajti J; Szok D; Csáti A; Vécsei L Expert Opin Pharmacother; 2023 Jun; 24(8):947-958. PubMed ID: 37038933 [TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model. Thaliffdeen R; Yu A; Rascati K Clin Drug Investig; 2024 Mar; 44(3):209-217. PubMed ID: 38381352 [TBL] [Abstract][Full Text] [Related]
13. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review. Dos Santos JBR; da Silva MRR Eur J Pharmacol; 2022 May; 922():174902. PubMed ID: 35358493 [TBL] [Abstract][Full Text] [Related]
15. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment. Tepper SJ Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830 [TBL] [Abstract][Full Text] [Related]
16. A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine. Argyriou AA; Mantovani E; Mitsikostas DD; Vikelis M; Tamburin S Expert Rev Neurother; 2022 Jun; 22(6):469-488. PubMed ID: 35707907 [TBL] [Abstract][Full Text] [Related]
18. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention. Caronna E; Alpuente A; Torres-Ferrus M; Pozo-Rosich P Handb Clin Neurol; 2024; 199():107-124. PubMed ID: 38307640 [TBL] [Abstract][Full Text] [Related]
19. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine. Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325 [TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials. Rizzoli P; Marmura MJ; Robblee J; McVige J; Sacco S; Nahas SJ; Ailani J; De Abreu Ferreira R; Ma J; Smith JH; Dabruzzo B; Ashina M J Headache Pain; 2024 Mar; 25(1):35. PubMed ID: 38462625 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]